Table S1. Baseline characteristics of the study group.

Baseline	**Total cohort (N=16)**
Males	10 (62,5%)
Female	6 (37.5%)
Median age at disease diagnosis; mth, yrs	33.7 mth (6.6 mth – 4.5 yr)
Median age range at vedo initiation; yrs	6.5 (2.2 – 16.5)
Crohn's disease	4/16 (25%)
Ulcerative colitis	12/16 (75%)
IFX exposure	15/16 (93.75%)
ADA exposure	9/16 (56.3%)
Other biologics exposure	4/16 (25%)
IFX discontinuation reason: - non-response - allergic reaction - loss of response - other	9/15 (60%) 3/15 (20%) 1/15 (6,7%) 2/15 (13,3%)
ADA discontinuation reason:	

- non-response - allergic reaction - loss of response - other	6/9 (66.7%) 0/9 2/9 (22.2%) 1/9 (11.1%)
Previous conventional therapies - Systemic steroids - Budesonide MMX - 5-ASA - Azathioprine therapy - Cyclosporin therapy	 16 (100%) 8 (50%) 15 (93.8%) 14 (87.5%) 10 (62.5%)
FCP; ug/g	1943.1

Abbreviations:

Months – mth

Years – yr

Vedolizumab - vedo

Infliximab – IFX

Adalimumab – ADA

5-aminosalicylate acid – 5-ASA

Body Mass Index – BMI

Pediatric Crohn's disease Activity Index - PCDAI

Pediatric Ulcerative Colitis Index – PUCAI

Fecal calprotectin – FCP

Table S2. Patient's characteristics after vedolizumab initiation compering to baseline.

N=16	**Baseline**	**4th dose week**	**10th dose week**
Median BMI: percentile	40	40	39
Laboratory parameters			
- mean Hemoglobin; mmol/l	10.5	11.8	11,7
- mean ESR; mm/h	29	18	19
- mean Albumin; g/l	38.5	42.9	41,3
Adverse events/ No of patients	0	1	-
-infection of the upper respiratory tract			
- arthralgia	0	0	2

PCDAI - pediatric Crohn's disease activity index.

PUCAI - Pediatric Ulcerative Colitis Index

BMI – body mass index

ESR - Erythrocyte sedimentation rate

Table S3. Relationship between vedolizumab and surgery in 3 patients who underwent surgery.

Patient	**Number of doses of vedolizumab**	**Number of weeks between vedolizumab commencement and surgery procedure**	**Number of weeks between last dose of vedolizumab and surgery procedure**
Patient A	3	13	6
Patient B	3	108	102
Patient C	9	58	6



Figure S1. Patients' disease clinical activity (PCDAI for CD and PUCAI for UC) between baseline and after vedolizumab commencement (4^{th} and 10^{th} week dose).



Figure S2. Values of fecal calprotectin for 8 patients tested for this marker before and after vedolizumab commencement.